Advertisement


Roland Seiler, MD, on Bladder Cancer: Subtypes and Treatment Response

2017 Genitourinary Cancers Symposium

Advertisement

Roland Seiler, MD, of the University of British Columbia, discusses a way to identify molecular subtypes of muscle-invasive bladder cancer, the varying responses to cisplatin-based neoadjuvant chemotherapy, and which patients show the most benefit. (Abstract 281)



Related Videos

Bladder Cancer

Roland Seiler, MD, on Bladder Cancer: Subtypes and Treatment Response (German Language Version)

Roland Seiler, MD, of the University of British Columbia, discusses in German a way to identify molecular subtypes of muscle-invasive bladder cancer, the varying responses to cisplatin-based neoadjuvant chemotherapy, and which patients show the most benefit. (Abstract 281)

Prostate Cancer

Paul L. Nguyen, MD, on Prostate Cancer: Active Surveillance

Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he co-chaired, which included discussion of Canadian vs U.S. guidelines; ProtecT; genomic and hereditary tests; and imaging to guide active surveillance. (General Session 1)

Solid Tumors

Lawrence H. Einhorn, MD, on Testicular Cancer: The Keynote Lecture

Lawrence H. Einhorn, MD, of the Indiana University Simon Cancer Center, summarizes his keynote lecture on the controversies in management of clinical stage I testicular cancer and the long-term consequences of platinum combination chemotherapy.

Prostate Cancer

Guru Sonpavde, MD, on Prostate Cancer: Targeting DNA Alterations

Guru Sonpavde, MD, of the UAB Comprehensive Cancer Center, discusses his study on circulating tumor DNA alterations in metastatic castration-resistant prostate cancer and the therapeutic direction the data suggest. (Abstract 149)

Kidney Cancer

Rana R. McKay, MD, on RCC: Continuing Benefit After Halting Treatment

Rana R. McKay, MD, of the University of California, San Diego, discusses study findings on PD-1/PD-L1 responders with metastatic renal cell carcinoma who discontinue therapy for immune-related adverse events. (Abstract 467)

Advertisement

Advertisement



Advertisement